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Traumatic injury of the central nervous system (CNS) has severe impact on the patients’
quality of life and initiates many molecular and cellular changes at the site of insult.
Traumatic CNS injury results in direct damage of the axons of CNS neurons, loss of myelin
sheaths, destruction of the surrounding vascular architecture and initiation of an immune
response. Class III semaphorins (SEMA3s) are present in the neural scar and influence a
wide range of molecules and cell types in and surrounding the injured tissue. SEMA3s and
their receptors, neuropilins (NRPs) and plexins (PLXNs) were initially studied because of
their involvement in repulsive axon guidance. To date, SEMA3 signaling is recognized to
be of crucial importance for re-vascularization, the immune response and remyelination.
The purpose of this review is to summarize and discuss how SEMA3s modulate these
processes that are all crucial components of the tissue response to injury. Most of the
functions for SEMA3s are achieved through their binding partners NRPs, which are also
co-receptors for a variety of other molecules implicated in the above processes. The
most notable ligands are members of the vascular endothelial growth factor (VEGF) family
and the transforming growth factor family. Therefore, a second aim is to highlight the
overlapping or competing signaling pathways that are mediated through NRPs in the same
processes. In conclusion, we show that the role of SEMA3s goes beyond inhibiting axonal
regeneration, since they are also critical modulators of re-vascularization, the immune
response and re-myelination.
Keywords: class III semaphorins, neuropilins, plexins, central nervous system trauma, axonal regeneration,
re-vascularization, immune response, re-myelination
HIGHLIGHTS
• Class III semaphorins (SEMA3s), apart from their classical
axon repulsive properties, exert regulatory functions in a vari-
ety of non-neuronal cells associated with CNS trauma.
• Neuropilins (NRPs) are pleiotropic receptors involved in multi-
ple signaling pathways controlling tissue remodeling following
CNS trauma.
• Semaphorin signaling is regulated at several levels, including
receptor complex formation, proteolytic cleavage and interac-
tion with extracellular matrix molecules.
• Interfering with class III semaphorin signaling might be bene-
ficial for axonal re-growth, re-vascularization, re-myelination
and manipulation of the immune response following CNS
trauma.
INTRODUCTION
The semaphorin family consists of secreted and transmembrane
glycoproteins that are involved in many cellular functions.
Semaphorins (SEMAs) are subdivided into eight classes based
on amino acid sequence similarities and structural features.
The first two classes of SEMAs are found in invertebrates, class
III till VII belong to vertebrates, while class VIII semaphorins are
only expressed by viruses (Semaphorin Nomenclature Committee
S. N., 1999). The first semaphorin, at that time named fasciclin
IV, was identified in the grasshopper and was later renamed
semaphorin1a (Kolodkin et al., 1992). SEMA3s are the best
described SEMAs and, like semaphorin1a, were initially identi-
fied by neurobiologists in an effort to identify proteins with an
effect on axon fasciculation, guidance and growth cone steering
(reviewed in Tran et al., 2007; Yoshida, 2012) and, somewhat later
as factors that affect neuronal polarization and synapse formation
during the development of the nervous system (reviewed in
Pasterkamp, 2012; Tillo et al., 2012).
The first member of SEMA3s, at that time designated
collapsin-1 and now referred to as Sema3A, was isolated from
the chick brain (Luo et al., 1993) and it was shown to induce
collapse of dorsal root ganglion (DRG) growth cones. This char-
acteristic gave rise to one of the most widely used bioassays to
study chemorepulsive proteins, the DRG growth cone collapse
assay. There are currently seven members of secreted SEMA3s,
named SEMA3A through SEMA3G. Their signaling is mediated
via heterodimer receptor complexes that contain neuropilins
as specific binding sub-units and plexins (PLXNs) as signal
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transduction sub-units. The compositions of receptor complexes
differ per SEMA3 member (reviewed in Sharma et al., 2012).
However, when functional receptor complexes are formed, down-
stream signaling cascades are activated that eventually propagate
SEMA3 biological responses.
Apart from the assorted binding specificity for NRPs and
PLXNs, SEMA3 signaling is modulated in a very complex and
diverse fashion. Firstly, the binding affinity of SEMA3s for NRPs
is regulated by furin dependent proteolytic cleavage resulting
in forms of SEMAs with different activity (Adams et al., 1997;
Parker et al., 2010, 2013; Guo et al., 2013). Secondly, SEMA3s
signaling is modulated by competition with other molecules that
signal via NRPs. For instance, NRPs act as co-receptors for the
vascular endothelial growth factor (VEGF) family (Soker et al.,
1998; Gluzman-Poltorak et al., 2000; Whitaker et al., 2001; Favier
et al., 2006; Prahst et al., 2008; Herzog et al., 2011), transform-
ing growth factors-β (TGF-β; Glinka and Prud’homme, 2008;
Glinka et al., 2011) and other growth factors such as epidermal
growth factor (EGF; Rizzolio et al., 2012) and platelet derived
growth factor (PDGF; Banerjee et al., 2006; Ball et al., 2010;
Cao et al., 2010; Pellet-Many et al., 2011). Moreover there are
indications that NRPs are able to interact directly with members
of the integrin family of surface receptors (Fukasawa et al., 2007;
Valdembri et al., 2009) in addition to the previously reported
regulation of integrin functions indirectly by SEMA3 signaling
(Barberis et al., 2004; Kruger et al., 2005; Serini et al., 2008).
Adding even more complexity to this wide array of interactions,
various molecules control the NRP-PLXNA receptor complex.
For example, the interaction of the complex with L1 cell adhe-
sion molecules (L1CAMs) or neuronal cell adhesion molecules
(NrCAMs) can modulate SEMA3 signaling towards repulsion or
attraction during axon guidance (Castellani et al., 2000, 2002;
Falk et al., 2005). Collectively the observations above demonstrate
that the signaling activity of SEMA3s can be regulated at multiple
levels, including proteolytic processing of SEMA3s, interaction
with other ligands and variation in receptor composition.
SEMA3s signaling plays a significant role following traumatic
central nervous system (CNS) injuries due to their presence in
neural scar tissue. The expression of SEMA3s following CNS
trauma is suggested to be important in both the acute and sub-
acute/chronic phases of scar formation. To date there is data
showing Sema3A mRNA up-regulation as early as 1 day after
CNS penetrating lesions (Pasterkamp et al., 1999), which becomes
more prominent at 7 days post-axotomy and persists for up to
2 months. In the above study, a significant increase in Sema3A
mRNA expression co-localized with several fibrotic markers but
not with glial cell or blood derived cell markers. De Winter et al.
(2002) validated these findings and expanded them with mRNA
expression patterns for more SEMA3 members, namely Sema3B,
C, E and F. The expression profile and time-course for the other
SEMA3s was similar to the findings from Pasterkamp et al. (1999),
however Sema3B expression was additionally detected in S100
positive cells in and around the lesion area, while a marked differ-
ence in expression patterns was observed between the transected
and contused spinal cord.
Other studies have reported a somewhat different Sema3A
mRNA expression pattern following spinal cord transection.
Hashimoto et al. (2004) found that Sema3A transcripts were
swiftly reduced in NeuN positive cells 24 h post spinal cord tran-
section and reached 80% of normal expression levels at 28d. How-
ever the same study failed to detect co-localization of Sema3A
with fibronectin (FN), in contradiction with most other studies.
The detection of SEMA3s at the protein level has been hampered
for a long time from the lack of reliable SEMA3 antibodies. Nev-
ertheless, with new commercial antibodies becoming available,
the expression of Sema3A protein has since been demonstrated
both in brain (Minor et al., 2011) and spinal cord injuries (SCI;
Mire et al., 2008). Sema3A was consistently found in the fibrotic
component of the scar indicating that the main source are the
meningeal cells invading the lesion core, in line with previous
findings on the localization of the SEMA3 mRNAs (Pasterkamp
et al., 1999; Niclou et al., 2003). There are indications that
SEMA3A and SEMA3F might also be expressed from glial cells
under stress conditions as shown in chronic phases of multiple
sclerosis (MS) lesions (Williams et al., 2007; Piaton et al., 2011;
Boyd et al., 2013).
On the other hand, the presence and source of SEMA3s during
the acute phase following induction of CNS trauma has been until
recently unsubstantiated. In earlier studies Sema3A mRNA was
localized in the vicinity of blood vessels, implying that disruption
of the vasculature causes a temporal upregulation of this protein
(Pasterkamp et al., 1999). However, the lack of co-localization
with several blood-derived cell markers indicates that the inclu-
sion of additional cell markers is of critical importance for future
studies. More recently, there is a distinct line of evidence which
indicates that SEMA3s are expressed in vitro in human peripheral
blood monocytes and monocyte-derived M2-like macrophages
(Ji et al., 2009) and from T-cells and dendritic cells (DCs) upon
activation by inflammatory cytokines (Lepelletier et al., 2006).
These findings corroborate in vivo observations in brain injuries,
where Sema3A was found to be expressed in the extracellular
space after focal cerebral ischemia after 2 h, 4 h and 8 h of reper-
fusion (Jiang et al., 2010). Additionally in a similar experimental
stroke model, Sema3A was upregulated 1 day following injury
onwards and partially co-localized with endothelial and neuronal
cells (Pekcec et al., 2013). Finally, a potential source of SEMA3s in
the acute phase might be the neurons themselves, since ischemic
neurons are known to secrete Sema3A in response to hypoxia
conditions affecting both microglia functions (Majed et al., 2006)
and revascularization efficacy (Joyal et al., 2011). Consequently,
it is currently well established that SEMA3s are highly expressed
in the acute and subacute/chronic phases of CNS trauma. As
discussed below this may have obvious implications for neural
scar tissue remodeling.
The neural scar is a complex tissue that consists of many cell
types including, astrocytes and other glial cells, various blood-
borne cells, fibroblast, and neural precursor cells, and thus it
constitutes a physical and molecular barrier that can block nerve
regeneration (reviewed in Silver and Miller, 2004). SEMA3s are
regarded as one of the major classes of axon repulsive molecules
that contribute to the failure of axons to regenerate through the
neural scar. Apart from their direct influence on axonal regener-
ation (reviewed in Pasterkamp and Verhaagen, 2006), there is a
wealth of data in the literature that suggests a role for SEMA3s
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and their receptors in the modulation of the immune response
(reviewed in Mizui et al., 2009; Takamatsu and Kumanogoh, 2012;
Kumanogoh and Kikutani, 2013), re-vascularization (reviewed in
Geretti et al., 2008; Neufeld and Kessler, 2008; Sakurai et al., 2012)
and re-myelination (reviewed in Kotter et al., 2011). The aim of
this literature review is to highlight these additional functions of
semaphorin signaling and to discuss these in the context of the
injured adult CNS.
THE ROLE OF SEMAPHORIN SIGNALING IN AXONAL
REGENERATION
Traumatic CNS injury has a severe impact on all cell types in the
injured neural tissue. One of the major obstacles for regeneration
is that axons of CNS neurons do not re-grow after injury. The
poor intrinsic neuronal growth capacity of CNS neurons and
the inhibitory extrinsic environment contribute to the failure
of axonal regeneration (reviewed in Afshari et al., 2009). Three
major classes of axon repulsive molecules are identified at the site
of injury: (1) myelin-derived axon repulsive molecules; (2) chon-
droitin sulfate proteoglycans (CSPGs); and (3) classical repulsive
axon guidance molecules. The best-characterized myelin-derived
axon repulsive molecules are reticulon 4 (Nogo-A), myelin associ-
ated glycoprotein (MAG) and oligodendrocyte-myelin glycopro-
tein (OMgp) (reviewed in Xie and Zheng, 2008). CSPGs located in
the extracellular matrix of the glial scar are structurally modified
and drastically up regulated after traumatic CNS injury. Most
isoforms of CSPGs restrict axonal regeneration (reviewed in Kwok
et al., 2011). Over and above, classical axon guidance molecules
including ephrins, slits, wnts, and SEMAs limit neural regenera-
tion following injury (reviewed in Harel and Strittmatter, 2006;
Niclou et al., 2006; Pasterkamp and Verhaagen, 2006; Giger et al.,
2010). From the latter, SEMA3s have been extensively studied due
to their predominant inhibitory properties for axonal outgrowth
during the development of the CNS.
Several studies interfered with distinct inhibitory compo-
nents of the neural scar after CNS injury with the rationale
to overcome the axon repulsive environment and stimulate
axonal regeneration and functional recovery. Axon repulsive
molecules in the extracellular matrix are commonly targeted by
the bacterial enzyme chondroitinase ABC (ChABC) and a small
CSPG called Decorin. ChABC digests the chondroitin sulphate
(CS)— glycosaminoglycan (GAG) chains of CSPGs, while decorin
suppresses multiple repulsive proteoglycans in the extracellular
matrix. Among the repulsive molecules that could be affected
from treatment with the above approaches is SEMA3A which in
earlier in vitro studies was shown to be removed from the surface
of cultured neuronal cells upon ChABC treatment (De Wit et al.,
2005). Later in vivo evidence demonstrated that the association of
Sema3A to the ECM can indeed be reduced by ChABC (Dick et al.,
2013; Vo et al., 2013) and decorin treatments (Minor et al., 2011).
This is particularly interesting since both approaches have been
reported to be beneficial for functional recovery after CNS injury
(Bradbury et al., 2002; Davies et al., 2004; Soleman et al., 2012 and
reviewed in Kwok et al., 2011). The ChABC and Decorin studies
confirmed that targeting the CSPGs and associated repulsive com-
ponents in the extracellular matrix results in a more permissive
environment for injured axons to re-grow. Thus, interference with
repulsive axon guidance molecules in the scar such as SEMA3s
may be a potential treatment for traumatic CNS injuries.
Accordingly, several studies aimed to block neuronal sensitiv-
ity to SEMA3s by modulating multiple semaphorin receptor com-
plexes. Application of an L1 mimetic peptide prevented the effects
of Sema3A on axon growth inhibition and growth cone collapse
in vitro, but was unable to enhance axonal regeneration and
functional recovery after SCI in vivo (Mire et al., 2008). Knock-out
of multiple receptor components for Nogo-A, MAG and Sema3s
in mice was unable to enhance regeneration of the axons of
serotonergic neurons after complete spinal cord transection. The
axons of mice that are deficient in Nogo receptor 1 (NgR1) and the
semaphorin signal transducing receptors PLXNA3 and PLXNA4
were unable to penetrate through the repulsive environment of
the neural scar (Lee et al., 2010). This would suggest that other
extrinsic factors in the scar tissue, in addition to myelin-derived
axon repulsive molecules and SEMA3s are capable to restrict
axonal regeneration.
On the other hand inhibition of SEMA3A itself seems like a
more efficient approach. A peptoid called semaphorin induced
chemorepulsion inhibitor (SICHI) enhances axonal regeneration
in an in vitro axotomy model of adult hippocampal slices (Mon-
tolio et al., 2009). In vivo, anti-Sema3 antibody treatment rescues
retinal ganglion cells (RGCs) from Sema3A-induced apoptosis
after optic nerve axotomy (Shirvan et al., 2002). Another Sema3A
inhibitor called Xanthofulvin (SM-216289) (Kumagai et al., 2003)
strongly interferes with NRP1 activation and consequently the
Sema3A induced growth-cone collapse and repulsive activity in
embryonic DRG explants. Furthermore, chronic administration
of Xanthofulvin enhanced olfactory nerve regeneration after axo-
tomy in vivo (Kikuchi et al., 2003) and promoted a regenerative
response and functional recovery after a complete spinal cord
transection (Kaneko et al., 2006). More specifically, the inhibition
of Sema3A reduced apoptosis, decreased the cavity volume of the
scar, increased the number of regenerating fibers expressing NRP1
into the scar, led to robust Schwann cell migration into the lesion,
promoted re-myelination, and enhanced angiogenesis. However it
should be noted that Xanthofulvin is a potent Sema3A inhibitor,
but additionally interferes with the signaling pathways of ephrins,
epidermal growth factor receptors (EGFRs) and fibroblast growth
factor receptors (FGFRs; Kaneko et al., 2006 suppl.). Collectively,
the latter studies demonstrated that Sema3A contributes to the
failure of CNS axonal regeneration in vivo and additionally inter-
feres with cellular responses that could support recovery after
CNS trauma.
SEMA3s have a high affinity for NRPs that act as co-receptor
for multiple ligands. One of the other molecules that signals via
NRPs are VEGFs (reviewed in Olsson et al., 2006) and compete
with SEMA3s for NRP binding (Gu et al., 2002; Appleton et al.,
2007). VEGFs are crucial players in angiogenesis (as discussed in
the next section on re-vascularization) and have been suggested
to also exert a direct neuroprotective role. The first evidence for
a neuroprotective role of VEGFs came from an in vitro model
of cerebral ischemia. VEGF rescued cultured CNS neurons from
hypoxia and glucose deprivation induced apoptosis (Jin et al.,
2000). Accordingly, in vivo administration of VEGF in the acute
phase after focal ischemic brain injury, prevented neuronal cell
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death and was found to enhance neurogenesis in chronic stages
(Sun et al., 2003). This is of particular interest since in a similar
in vivo situation Sema3A is implicated in cerebral ischemia-
induced neuronal death (Jiang et al., 2010) highlighting the dual
ligand interaction capacity of NRP1-signaling following brain
injury.
Taken together the above experimental data indicate that
SEMA3s are present in scar tissue and have a negative impact
on axonal regeneration by inducing apoptosis and repulsion
of axons of CNS neurons. Several studies have demonstrated
that targeting the SEMA3s receptors at injured neurons alone is
insufficient to promote axonal regeneration. However, inhibition
of Sema3A itself was shown to improve various regenerative
processes. In addition to their direct effects, SEMA3s compete
with multiple ligands for NRP binding including the neuropro-
tective VEGFs. Therefore it cannot be ruled out that by directly
targeting SEMA3s, the binding sites at NRPs become available
for interaction with VEGFs for example thus offering yet another
mechanism that may prevent neural apoptosis. Furthermore,
direct targeting of SEMA3s could influence the complex process
of tissue remodeling in and around the lesion area as outlined
further in this review. Disruption of the vascular architecture,
the inflammatory response and the loss of axonal myelin sheaths
following CNS trauma are factors that additionally influence
neural tissue and functional recovery and appear to be sensitive to
SEMA3 signaling. From this perspective, the impact of blocking
semaphorin signaling following CNS trauma goes beyond influ-
encing axonal guidance and regeneration.
THE ROLE OF SEMAPHORIN/VEGF SIGNALING IN
RE-VASCULARIZATION
One of the hallmarks of CNS trauma is damage to the sur-
rounding vascular architecture. Acute rupture of the blood ves-
sels after CNS injury initiates a secondary injury response that
drastically limits the regenerative capacities of injured CNS neu-
rons (reviewed in Oudega, 2012). Firstly, the decreased blood
supply causes ischemia-induced apoptosis of neurons and glial
cells (Casella et al., 2006). Secondly, breakdown of the blood-
brain barrier (BBB)/blood-spinal cord barrier (BSCB) results in
oedema formation. Furthermore, the increase in vascular perme-
ability allows foreign molecules and inflammatory cells to enter
the injury site (reviewed in Engelhardt and Coisne, 2011). The
permeability of the BSCB is maximal around 24 h following SCI
but is gradually restored to normal after 14 days (Figley et al.,
2014). The BBB permeability after traumatic brain injury may
differ from BSCB permeability after spinal injury due to morpho-
logical differences (reviewed in Bartanusz et al., 2011). However,
the re-establishment of new blood vessels following CNS injury,
often referred to as angiogenesis or re-vascularization, is of key
importance for functional recovery after a CNS injury.
The ischemic and hypoxic conditions after traumatic CNS
injury triggers re-vascularization by up-regulating angiogenic
growth factors. However, new blood vessels are mainly formed
during the first week of injury (Figley et al., 2014) indicating
that the endogenous angiogenic capacity is mostly restricted
to the early phase following CNS injury. The VEGF family
constitutes the key angiogenic growth factors since they stimulate
blood vessel growth by endothelial cell (EC) migration, survival
and proliferation. The mammalian VEGF family consists of five
secreted glycoproteins named VEGFA, B, C, D and placental
growth factor (PGF). Alternative splicing of the mRNAs encoding
the VEGF members results in a plethora of splice variants with
different activity and binding affinities for receptors (reviewed
in Olsson et al., 2006; Adams and Eichmann, 2010). The splice
variants of VEGFA are secreted by various cell types at the injury
site including astrocytes (Bartholdi et al., 1997; Herrera et al.,
2009), microglia (Chen et al., 2013) and invading inflammatory
cells (Sköld et al., 2000).
VEGFA is extensively investigated in re-vascularization due to
the rapid upregulation of this VEGF member and its receptors
after CNS injury (Sköld et al., 2000; Pugh and Ratcliffe, 2003;
Widenfalk et al., 2003; Chen et al., 2013). Notably, the observed
drop in VEGFA expression during later stages of recovery after
CNS trauma (Sköld et al., 2000; Vaquero and Zurita, 2004;
Herrera et al., 2009) correlates with the limited endogenous
angiogenesis capacities. This suggests that VEGFA is important
for the endogenous re-vascularization early after CNS injury and
thus became the focus of research in therapeutic angiogenesis,
which aims to extend the time window of blood vessel formation
in order to improve blood supply and neuronal survival after
CNS trauma. Application of VEGFA and more specifically its
VEGF165 splice variant was shown to stimulate angiogenesis after
CNS trauma in brain (Sun et al., 2003; Zechariah et al., 2013)
and spinal cord (Facchiano et al., 2002; Widenfalk et al., 2003;
De Laporte et al., 2011). However, it is still controversial whether
VEGFA/VEGF165 treatment improves or aggravates neural and
functional recovery (reviewed in Kundi et al., 2013). The results
of recent studies are summarized in Table 1. This controversy
stems majorly from differences in study design that could greatly
influence the experimental outcome, while on the other hand it
should be noted that re-vascularization after injury is regulated
by multiple EC growth factors, including the other members of
the VEGF-family, e.g., angiopoietins, fibroblast growth factors
(FGFs) and PDGFs (Benton et al., 2009; Carmeliet and Jain,
2011; Lieu et al., 2011). Hence, other modulators of angiogenesis
may interfere with the angiogenic potential of VEGFA treatments
particular in chronic stages of traumatic CNS injury. We hypoth-
esize that one mechanism could be that injury induced SEMA3s
compete with VEGFs during the (sub)chronic phases of CNS
trauma.
VEGF signaling is mediated by tyrosine kinase receptors
(VEGFR1, VEGFR2, and VEGFR3) and receptor complexes con-
sisting of NRPs and VEGFRs (Gluzman-Poltorak et al., 2000;
Whitaker et al., 2001; Favier et al., 2006). Activation of NRP-
VEGFR complexes lead to enhanced VEGF signaling in ECs
(Soker et al., 1998; Herzog et al., 2011). Blockage of endoge-
nous VEGF165 binding to NRP1 reduces vascular permeability
and micro-hemorrhage formation after 24 h of experimentally
induced BBB disruption in mice (Suidan et al., 2012). Knock-
in mice expressing a mutated NRP unable to bind VEGF165,
are viable but develop post-natal angiogenesis defects in hearth
and retina (Fantin et al., 2014). This indicates that NRP1 is an
essential component of VEGF signaling and that growth factors
other than VEGF165 might also contribute to angiogenesis and
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Table 1 | Summary of experimental studies that assessed the therapeutic angiogenic potential of VEGF after CNS trauma.
Growth factor
supplied
Injury
model
Time of delivery Delivery
method
Main findings Reference
spinal cord
hemisection
gelfoam with
growth factor
- improves angiogenesis
- enhances tissue sparing
- promotes axonal sprouting
Facchiano et al. (2002)
- improves angiogenesis
- enhances tissue sparing
- reduces apoptosis
- improves locomotor recovery up to
6 weeks after injury
Widenfalk et al. (2003)
acute (immediately
following injury)
single
injection
- reduces cavity formation
- enhances tissue sparing
Sundberg et al. (2011)
VEGF165 spinal cord
contusion
- no effect on locomotor recovery
- increases incidence of allodynia
- no effect on tissue sparing Herrera et al. (2009)
gelfoam with
growth factor
- elevates BSCB permeability
- improves locomotor recovery up to
4 weeks but diminishes on 8
weeks after injury
Patel et al. (2009)
acute - subchronic
(0–7 days post injury)
daily
injections
- reduces mechanosensitivity
van Neerven et al. (2010)
- no effect on thermal sensitivity
- no effect on motor functions
- no effect on tissue sparing
subchronic (3 days
post injury)
single
injection
- no effect on angiogenesis
- increases vascular permeability
- increases leukocytes infiltration
- exacerbates histopathology
Benton and Whittemore (2003)
subchronic - chronic
(3–21 days post
injury)
- improves angiogenesis
- reduces infarct volume
- reduces inflammatory response
- enhances pericyte functions
Zechariah et al. (2013)
VEGF
focal
cerebral
ischemia
subacute - subchronic
(1–3 days post injury)
daily delivery
by osmotic
pumps
- improves angiogenesis
- reduces infarct volume
- acute neuroprotective effects
- improves neurological
performances
Sun et al. (2003)
VEGF165 and
FGF2
spinal cord
hemisection
acute - subchronic
(0–7 days post injury)
implantation
of protein
loaded
channel
bridges
- improves angiogenesis
De Laporte et al. (2011)
- no effect on axonal regrowth
This table highlights the opposing effects of VEGFA administration after CNS trauma reported by different laboratories. The contradiction in the outcome of VEGF
treatment may arise from technical differences in study design, while the different assessment approaches do not allow for direct comparison of the studies. In this
table, the literature on VEGF is organized according to type of VEGF applied, the injury model, time of delivery and the delivery method. The main findings of each
paper are summarized and the colors indicate whether the results are considered to be positive (green), absent or negative (red). All studies used rat as experimental
animal except Zechariah et al. (2013) who used mice.
re-vascularization. Similar to VEGFs, SEMA3s are up-regulated
after traumatic CNS injury and their signaling is mediated via
NRP complexes. Recent findings suggest that SEMA3s play an
inhibitory role in re-vascularization after injury thus suggesting
a potential interplay between SEMA3s and VEGF after neural
trauma.
Classical axon guidance molecules, including SEMA3s and
their receptors, play an import role in the development of
the vascular system (Carmeliet and Tessier-Lavigne, 2005).
Injury induced SEMA3s may act directly on ECs and inhibit
revascularization. One of the working hypotheses is that SEMA3s
compete with VEGF165 for binding to NRPs at ECs. The func-
tional competition between both ligands arises by overlap in the
binding areas at the NRP receptors. The NRP b1b2 domains
are essential for VEGF165 binding (Herzog et al., 2011), while
SEMA3s requires both the a1a2 and b1 domains for NRP interac-
tion (Gu et al., 2002; Geretti et al., 2007, 2008; Herzog et al., 2011).
Moreover, the stereological conformation of the NRPs allows only
one type of ligand interaction. Indeed, Sema3s were found to
compete with VEGFs for neuropilin receptors in binding assays
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in vitro. Sema3A is a competitor for VEGF165 at NRP1 (Miao
et al., 1999); while Sema3F interferes with VEGF165 binding at
both NRP1 and NRP2 (Geretti et al., 2007; Parker et al., 2010).
In line with these structural observations, Sema3A and Sema3F
inhibit VEGF165 induced ERK1/2 activity and EC proliferation
in vitro (Kessler et al., 2004; Guttmann-Raviv et al., 2007).
Moreover, Sema3A interferes with the chemotactic properties of
VEGF165 on ECs expressing NRP1 in vitro (Miao et al., 1999)
and VEGF165-induced angiogenesis in vivo (Acevedo et al., 2008).
Taken together, the characteristic structure of NRPs and the
functional competition between SEMA3s and VEGF165 support
a role for SEMA3s as inhibitors of the pro-angiogenic effects of
VEGF165.
Alongside the direct competition with VEGFs for NRP bind-
ing, semaphorin signaling itself has a wide spectrum of anti-
angiogenic effects. The role of SEMA3s and their receptors in
angiogenesis have been studied in cell cultures, cancer tissue and
in the CNS related to pathology of the retina. Various assays
of cultured ECs demonstrated that SEMA3s affect the function
of ECs. Sema3A inhibits cell motility and initiates the collapse of
the cytoskeleton of ECs expressing NRP1 (Miao et al., 1999).
Similarly, human recombinant SEMA3F induces cytoskeleton col-
lapse of EC expressing NRP2 (Shimizu et al., 2008). Therefore,
Sema3A and SEMA3F are chemorepulsive for ECs and inhibit
their proliferation in culture. Interestingly, these effects do not
depend on competition for NRPs binding with VEGF165 as shown
in cultures that do not contain this growth factor. Most impor-
tantly, the repulsive and anti-proliferation effects of Sema3A and
SEMA3F on EC are synergistic in vitro. The expression levels
of different SEMA3s after injury may therefore be important
since high concentrations of Sema3A and SEMA3F induces ECs
apoptosis in vitro (Kessler et al., 2004; Guttmann-Raviv et al.,
2007).
In addition to Sema3A and SEMA3F, SEMA3B affect ECs
that express NRP1 and NRP2. SEMA3B signaling repels ECs,
inhibits cell adhesion, causes collapse of the cytoskeleton, reduces
VEGF165 induced ERK1/2 phosphorylation and apoptosis in vitro
(Varshavsky et al., 2008). Notably, Varshavsky et al. demonstrated
that furin dependent proteolytic cleavage of SEMA3B reduces
the activity of this semaphorin and its effects on ECs. Moreover,
transcriptome screening of the ECs in vitro and in mammalian
tissue demonstrated that another SEMA3, Sema3G is expressed in
vascular tissue (Kutschera et al., 2011). The latter study further-
more showed that recombinant Sema3G stimulates denudation
(clearance of surface receptors) of ECs that were cultured on
smooth muscle cells. This suggests that Sema3G stimulates EC
functions to form new blood vessels. Collectively, SEMA3s affect
the function of ECs directly (independent of VEGF) and may
have an inhibitory role in angiogenesis. However, one exception
appears to be Sema3G that serves as a positive regulator of
angiogenesis in vitro.
Even though there is an explicit need in investigating SEMA3s
in the injured nervous system in the context of re-vascularization,
to date the majority of evidence originates from the field of
cancer biology. In this field of research, it is evident that several
SEMA3s concomitantly target endothelial and cancer cells and
can strongly restrict angiogenesis and tumor growth, rendering
them a principal anti-tumor therapeutic target (reviewed in
Tamagnone, 2012). Accordingly, the seven members of SEMA3s
and NRP receptors are heterogeneously expressed at the mRNA
level in many human glioma tumors (Karayan-Tapon et al., 2008).
Several studies investigated the effects of SEMA3s on tumor
angiogenesis in vivo. Tumors that express SEMA3A (Maione et al.,
2009; Casazza et al., 2011) SEMA3B (Rolny et al., 2008), SEMA3D
(Sabag et al., 2012), Sema3E (Sakurai et al., 2010) or SEMA3F
(Bielenberg et al., 2004; Kessler et al., 2004) have a disorganized
vesicular architecture compared to controls. Most of the tumors
that express SEMAs have fewer, smaller or less branched blood
vessels. Blood vessels in tumors expressing SEMA3B have deficits
in the recruitment of pericytes, which normally stabilize EC tube
formation (Rolny et al., 2008). In contrast to the in vivo findings
reported from Kutschera et al., SEMA3G inhibits angiogenesis
in experimentally generated tumors in vivo, which were derived
from a glioblastoma cell line and implanted in the cortex (Sabag
et al., 2012). Thus, SEMA3 signaling in tumors influences ECs and
pericytes and is inhibitory for tumor angiogenesis in vivo.
Semaphorins also affect re-vascularization in the CNS. In
proliferative retinopathies (PRs), there is degeneration of the
vascular architecture and the hypoxic regions display dysregulated
hyper revascularization. Interestingly, the newly formed blood
vessels are not capable to reach the neural retina. The inflam-
matory and ischemic stress induced expression of Sema3A by
RGCs prevented revascularization of the eye since RGC-derived
Sema3A repelled blood vessels and inhibited EC growth (Joyal
et al., 2011). In addition, Sema3A signaling via NRP1 causes
loosening of EC junctions leading to vascular hyper permeability
and macular edema in vivo (Cerani et al., 2013). Sema3A is
unique among SEMA3s since it induces vascular permeability
via NRP1 (Acevedo et al., 2008). On the other hand, inhibition
of CNS angiogenesis appears to be mediated also by Sema3E
that signals via PlexinD1, in a NRP1-independent fashion. In
particular, ischemic neurons secrete Sema3E, which mediates the
retraction of endothelial filopodia by activating small GTPases
like RhoJ. In a mouse model of ischemic retinopathy, silencing of
PLXND1 signaling enhanced re-vascularization at the extraretinal
area of the eye. Consistently, the number of extraretinal vessels
was decreased following intravitreal injection of Sema3E protein
(Fukushima et al., 2011). This demonstrates that Sema3E and
PLXND1 signaling inhibits angiogenesis in ischemic retinopathy
in vivo.
At least part of the observed SEMA3s functions are mediated
through regulation of integrins. Integrin receptors are located
on the cell surface of ECs and have a major role in angiogenesis
by promoting EC adhesion, migration and survival. There are
twenty-four unique heterodimers of integrin receptors that bind
to a wide range of ligands in the extracellular matrix (reviewed in
Avraamides et al., 2008). SEMA3 signaling can modulate integrin
receptors at ECs and thereby influence angiogenesis. Sema3A and
Sema3F inhibit integrin-mediated adhesion and migration of
cultured ECs on FN and vitronectin (VN) substrates. Accordingly,
interference with NRP1 and PLXNA1 signaling enhanced
adhesion and migration on these integrin ligands (Serini et al.,
2003). In addition to Sema3A and Sema3F, Sema3E suppresses the
function of integrins and could lead to loss of integrin-mediated
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adhesion to the extracellular matrix (Sakurai et al., 2010). The
same study revealed some of the mechanisms how Sema3E
negatively regulates the availability of integrin receptors at the
cell surface. Firstly, Sema3E signaling via PLXND1 leads to inac-
tivation of Ras-related protein (R-Ras), which in turn, inactivates
integrin receptors. Secondly, Sema3E induces the activation of
ADP-ribosylation factor 6 (Arf6) positive vesicles that promote
internalization of integrin receptors. In contrast to these functions
of SEMA3s as inhibitors of angiogenesis and integrin functions,
Sema3C promotes angiogenesis in vitro by activation of integrins
(Banu et al., 2006). Collectively, the aforementioned studies
propose yet another mechanism on how SEMA3s might affect re-
vascularization, namely by modulating the function of integrins.
Reestablishing the metabolic supply to neurons may acceler-
ate regeneration and could be required for functional recovery
after traumatic CNS injury. The opposing functions of VEGFA
and SEMA3s on ECs may limit the endogenous angiogenic
capacities after CNS trauma. The relative expression of VEGFA
and SEMA3s over time could therefore drastically influence re-
vascularization, where VEGFA would be beneficial and Sema3s
would limit vascularization. VEGFA is highly expressed in early
re-vascularization stages and contributes to endogenous repair of
the vascular architecture. In the sub-chronic and chronic stages,
VEGFA expression declines while the expression of SEMA3s rises.
The injury-induced expression of SEMAs could compromise vas-
cular repair after CNS trauma. Firstly, SEMA3s interfere with the
VEGFA pro-angiogenesis effects by direct competition for NRPs.
SEMA3s could additionally modulate bFGF and PDGF signaling,
via NRPs, that also influence angiogenesis. Secondly, SEMA3s
expressed by ischemic neurons and meningeal fibroblasts could
have a wide spectrum of anti-angiogenesis effects by regulating
EC adhesion, migration, proliferation, survival and recruitment
of pericytes. The effects of SEMA3s on angiogenesis may be
mediated or depend on the modulation of cell surface receptors
such as integrins. Future studies should focus on the question
whether inhibition of various SEMA3s could therefore promote
revascularization and additionally make the neural scar more
permissive for regenerating axons. Kaneko et al. (2006) showed
that application of the sema3A inhibitor Xanthofulvin in the
injured spinal cord indeed promoted axonal regeneration and
angiogenesis at the lesion site. This observation is in line with the
inhibitory role of SEMA3s on re-vascularization after traumatic
CNS injury.
THE ROLE OF SEMAPHORIN SIGNALING IN MODULATION OF
THE IMMUNE RESPONSE AFTER CENTRAL NERVOUS
SYSTEM TRAUMA
There is growing literature that indicates that members of sev-
eral classes of SEMAs (including SEMA3s) and their recep-
tors are key modulators of the immune response (reviewed
in Mizui et al., 2009; Takamatsu and Kumanogoh, 2012;
Kumanogoh and Kikutani, 2013), hence they constitute a
family of immunoregulatory molecules that are collectively
termed “immune SEMAs”. A variety of mature and differ-
entiating immune cells are susceptible to SEMA3s signaling
pathways that drive biological processes as diverse as cell
migration, apoptosis and modulation of the immune response
at the level of cytokine release. The trauma-induced expres-
sion of SEMAs may therefore drastically influence the immune
response. This part of the review highlights the role of
SEMA3s and does not include the well-documented role of
membrane-bound SEMAs in the immune response (reviewed
in Chavarría and Cárdenas, 2013; Kumanogoh and Kikutani,
2013).
Traumatic CNS injury initiates a profound immune response
in which many molecules and cells are involved (reviewed
in Donnelly and Popovich, 2008; Hawthorne and Popovich,
2011). Astrocytes (reviewed in Pekny et al., 2014) and microglia
(reviewed in London et al., 2013) are among the first neuroglial
cells in the CNS that respond to trauma. The activated astrocytes
and microglia release pro-inflammatory cytokines that are toxic
for neural tissue. In addition to glial cells, neurons and oligoden-
drocytes (OLs) synthesize and secrete chemokines and cytokines
after trauma (reviewed in Chavarría and Cárdenas, 2013). In
the acute phase of injury proinflammatory cytokines such as
interleukins (IL-1, IL-6) and tumor necrosis factor (TNFα), are
highly expressed, while the “anti-inflammatory cytokines” such
as IL-4, TGF-β and reactive oxygen species are expressed in the
chronic stages (reviewed in Vidal et al., 2013). The infiltration
rate of inflammatory cells is enhanced due to the heavily disrupted
BBB/BSCB barrier after traumatic CNS injury (reviewed in Engel-
hardt and Coisne, 2011).
An elegant flow cytometry and immunohistochemical analysis
characterized the cellular inflammatory response over time after
SCI in rats (Beck et al., 2010). Neutrophils (e.g., granulocytes
and monocytes) are the first inflammatory cells that enter the
spinal cord at the day of insult. Monocyte-derived macrophages
start to infiltrate the injury site at 3 to 7 days post injury. T-
cells enter the injured spinal cord during the second week of
injury. In the chronic phase of the immune response (>14 days),
microglia/macrophages and lymphocytes are the most abundant
inflammatory cell type present in the spinal cord (Beck et al.,
2010). A study with human post-mortem tissue showed that a
similar chronologic order of cellular events occurs in patients
suffering from SCI, and that a lesion-induced immune response
could be observed years after trauma (Fleming et al., 2006). In
summary, microglia and neutrophils are the main cellular players
in the acute phase, while microglia, macrophages and lympho-
cytes are more dominantly involved in the later sub-chronic and
chronic phases of the immune response.
The role for the immune response after CNS trauma is com-
plex and is a topic of intense study. There are experimental studies
that addressed the role of the immune response by modulation of
cytokines (Lacroix et al., 2002; Ferguson et al., 2008; Genovese
et al., 2008; Zhou et al., 2009; Arnold and Hagg, 2011; White
et al., 2011; Sato et al., 2012) while other laboratories targeted
cellular components to stimulate repair following traumatic CNS
injury (Chernykh et al., 2010; Pineau et al., 2010; Wu et al.,
2012; Bachstetter et al., 2013; Shechter et al., 2013; Bartus et al.,
2014). The part of review below will illustrate that semaphorin
signaling could be a target to modulate the immune response after
traumatic CNS injury. The injury-induced SEMA3s influence the
release of various cytokines and cell types that take part in the
immune response.
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Macrophages are classified into two distinct populations,
which have opposing effects on neuronal tissue. The classical
pro-inflammatory type 1 macrophages (M1) secrete cytokines
that can be toxic for CNS neurons, while the non-classical
anti-inflammatory type 2 macrophages (M2) can promote neu-
roregeneration across neuronal repulsive substrates (reviewed in
David and Kroner, 2011). However, most macrophages in the
injured spinal cord are considered to be M1 macrophages (Kigerl
et al., 2009). SEMA3A influences the behavior of monocytes
and monocyte-derived macrophages. Cell migration assays have
demonstrated that SEMA3A inhibits the mobility of human
monocytes and a cell type derived from a B-cell lineage in
vitro (Delaire et al., 2001), an effect that was not observed for
SEMA3F. Interestingly, the above study suggested that SEMA3A
could signal via yet unidentified receptors to reduce the migration
of monocytes since expression of NRP1, the SEMA3A binding
receptor, was not detected. However, it should be taken into
account that the study was conducted at a time where many
receptor components of SEMA3 signaling were not fully identified
yet, and the tools to identify them were limited. Furthermore, a
more recent in vitro study demonstrated that differentiation of
human monocytes into M2 macrophages induces the expression
of NRPs, PLXNA1, PLXNA2, and PLXNA3 (Ji et al., 2009).
Notably, SEMA3A did not affect the migration and phagocytic
efficiency of these M-CSF derived M2 macrophages but it did
initiate cell death. In contrast, interferon-γ (IFNγ) driven dif-
ferentiation of monocytes into M1 macrophages down-regulates
NRP1 in vitro (Ji et al., 2009) and therefore M1 macrophages may
not be responsive to SEMA3A.
Thus, SEMA3A could induce apoptosis of monocyte-derived
M2 macrophages and inhibit the migration of their progenitor
cells in vitro. However in a demyelination model in vivo, the above
pro-apoptotic effects of SEMA3A on the macrophage response
were not validated (Syed et al., 2011). Administration of exoge-
nous Sema3A did not affect the phagocytic efficiency and amount
of macrophages after a demyelination lesion. Although a distinc-
tion in M1 or M2 macrophage subtypes was not made in the
latter study. Furthermore one can argue that this demyelination
model does not resemble a classical traumatic CNS injury model
due to the absence of BBB/BSCB breakdown. It would however be
interesting to determine whether Sema3A alters the macrophage
heterogeneity at the lesion site by selectively inducing apoptosis of
M2 macrophages expressing NRPs.
Other studies showed that lymphocytes, which are suggested
to limit functional recovery after CNS trauma (Wu et al., 2012),
are also influenced by SEMA3s. Firstly, Sema3A, Sema3E and
the receptors NRP1 and PLXND1 mediate the T-cell migra-
tion during T-cell maturation in the thymus (Lepelletier et al.,
2007; Choi et al., 2008 and reviewed in Mendes-da-Cruz et al.,
2012a,b). Although, it is unlikely that trauma-induced expression
of SEMA3s in the CNS influences T-cell maturation in the thy-
mus, one could argue that SEMA3s may repel T-cells at the injury
site. Secondly, SEMA3A secreted from tumor cells reduces the
proliferation of recruited T-cells and antagonizes the synthesis of
cytokines such as IL-2, IL-4, IL-10 and IFNγ in vitro (Catalano
et al., 2006) The inhibitory effect of SEMA3A on T-cells are
mediated by the activation of the member of RAS oncogene
family Rap1, which in turn, inhibits the phosphorylation of MAP
kinase-ERK kinase (MEK) and the mitogen-activated protein
kinase (ERK1/2) (Catalano et al., 2006). Thus, SEMA3s inhibit
the proliferation of recruited T-cells and decreases cytokine
production.
The chronic immune response is initiated when DCs present
antigens to T-cells in secondary lymphoid organs. The physi-
cal interaction between DCs and T-cells are mediated through
homophilic binding of NRP1 receptors. Blockage of NRP1 at both
cells interferes with the cell-cell contact and thereby reduces T-cell
proliferation (Tordjman et al., 2002). Hence, NRP1 receptors play
a major role in the initiation of the primary immune response.
Furthermore, SEMA3A signaling via NRP1 inhibits the dendritic-
contact mediated T-cell proliferation. SEMA3A impairs the polar-
ization of the actomyosin cytoskeleton and T-cell receptors (TCR)
at the DC-T cell contact zone. Moreover, SEMA3A inhibits TCR
mediated activation signals such as phosphorylation of the zeta-
chain associated protein kinase 70kDa (ZAP-70) and focal adhe-
sion kinase (FAK; Lepelletier et al., 2006). Consequently, SEMA3A
negatively regulates T-cell activation and proliferation. In line
with this observation, blockage of SEMA3A function results in
increased T-cell proliferation (Catalano et al., 2006; Lepelletier
et al., 2006). Finally, mice that lack PLXNA4, Sema3A, or contain
a NRP1 mutant that is not capable to bind Sema3s, show a
hyper proliferative T-cell and immune response after experimen-
tal autoimmune encephalomyelitis (Yamamoto et al., 2008). Thus,
trauma-induced expression of SEMA3s may therefore inhibit the
T-cell response at the site of injury suggesting that blockage of
Sema3A signaling could potentially enhance it.
SEMA3A influences DCs, which in turn, are important for
initiation of the immune response. SEMA3A modulates DCs
through NRP1 and PLXN signaling. A knock-out study showed
that PLXNA1 at DCs is required for normal T-cell activation and
their synthesis of cytokines IFNγ, IL-2 and IL-4 (Takegahara et al.,
2006). Furthermore, Sema3A signaling via PLXNA1 allows DCs
to enter the lymphatic system in vivo. Sema3A acts on the rear
side of DCs, enhances their migration speed and allows DCs to
pass EC-junctions by actomyosin contraction in vitro (Takamatsu
et al., 2010). Signaling via PLXNB2 and PLXND1 receptors did
not affect DC migration, but down-regulated the synthesis of pro-
inflammatory cytokine IL-12/IL-23p40 (Holl et al., 2012). Thus,
SEMA3s stimulates the migration of DCs into the lymphatic
system and influences their synthesis of cytokines.
Activated microglia are also sensitive to Sema3A. IFNγ medi-
ated activation of microglia in vitro induces the expression of
the Sema3A receptors NRP1 and PLXNA1, while their exposure
to exogenous Sema3A induces apoptosis in a NRP1 dependent
manner (Majed et al., 2006). The Sema3A mediated apoptosis was
validated in a model of toxin-induced focal brain injury in vivo,
where stressed neurons secreted Sema3A and microglia upreg-
ulated NRP1 after injury. The apoptotic microglia co-localized
with Sema3A in vivo (Majed et al., 2006), indicating that Sema3A
released from stressed neurons could induce death of injury-
activated microglia. There is controversy whether microglia are
beneficial or deleterious for recovery. Microglia can secrete reac-
tive oxygen species and pro-inflammatory cytokines that can
harm neurons, but may on the other hand have neuroprotective
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roles, i.e., by phagocytic clearance of toxic molecules and myelin
debris (reviewed in London et al., 2013).
Platelet cells are involved in the acute immune response
by neutralizing bacteria and they stimulate the activation of
neutrophils and DCs. Next to cell-cell interactions, platelet
cells secrete granules and cytokines that contribute to these
processes. For example, platelet cells contain high levels of
the pro-inflammatory IL-1β, anti-inflammatory cytokine TGF-β
and stimulate the DC-mediated synthesis of anti-inflammatory
IL-10 (reviewed in Semple et al., 2011). Platelet cells are sensi-
tive to SEMA3s through their expression of NRP1 and PLXNA
receptors (Kashiwagi et al., 2005). Sema3A inhibits platelet func-
tions including, granular secretion, adhesion to FN and platelet
spreading. This is achieved by inactivation of αIIβ3 integrin and
the Rho GTPase (RacI)-mediated cytoskeleton rearrangements
(Kashiwagi et al., 2005). To date, it is unknown whether SEMA3A
affect platelet cells in vivo following CNS trauma.
There are a number of competitors of SEMA3A signaling
in the immune system. NRPs are co-receptors for multiple lig-
ands such as VEGFs and TGF-β that compete for binding sites.
VEGFs enhance the permeability of blood vessels (reviewed in
Olsson et al., 2006) and therefore contribute to the infiltration
of inflammatory cells to the lesion site. Furthermore, VEGFs
are direct modulators of the immune response. Contrary to
SEMA3s, VEGFs act as pro-inflammatory cytokines by recruiting
monocytes and macrophages and activate them by inducing the
secretion of granulocyte-macrophage colony stimulating factor
(GM-CSF). At chronic stages, VEGFs can suppress the immune
response by inhibiting the maturation of DCs and impairing the
function of T-cells (reviewed in Vitale et al., 2010). After trau-
matic CNS injury, VEGFA is highly expressed for a relative short
period (Sköld et al., 2000; Vaquero and Zurita, 2004; Herrera
et al., 2009), and may therefore promote the immune response
in the acute phase of injury.
TGF-β is another key regulator of the immune response
and modulates the cell proliferation, differentiation, migration
and survival properties of immune cells. In the chronic stages
of injury, the role of this cytokine is mainly to suppress the
immune response. For instance, TGF-β influences macrophages
by inhibiting their activation, phagocytic efficiency and antigen
presentation capacity (reviewed in Li et al., 2006). Furthermore,
the interaction with NRP1 suppresses T-cells by inhibiting their
proliferation and production of pro-inflammatory cytokines like
IL-2 in vitro (Glinka and Prud’homme, 2008). TGF-β is highly
expressed after traumatic SCI and remains elevated up to a year in
humans (Buss et al., 2008). Therefore, the functional competition
among SEMA3s and TGF-β for binding to NRP1 appears to be of
particular interest.
Several studies have suggested that TGF-β can signal through
its canonical (Smad2/3) signaling, which is NRP1-independent,
exerting anti-proliferative and immunosuppressive effects that
induce fibrosis and non-canonical signaling pathway which
is NRP1-dependent and can antagonize canonical signaling
(reviewed in Prud’homme and Glinka, 2012). It is therefore
reasonable to assume that blocking SEMA3 activity might be
beneficial for tissue sparing by allowing NRP epitopes to inter-
act with this growth factor and therefore favoring the TGF-β
non-canonical signaling pathway. Thus, TGF-β signaling via
NRPs may contribute to control the immune response in chronic
stages of injury. Collectively, signaling of VEGFs and TGF-β via
NRP1 modulates the immune response after traumatic injury.
VEGFA may boost the immune response which could harm CNS
neurons in the acute phase of injury, while TGF-β suppresses the
immune response in chronic stages of injury.
Taken together these data indicate that SEMA3s influence
the function of many inflammatory cells including mono-
cytes, B-lymphocytes, M2 macrophages, T-lymphocytes, activated
microglia, DCs and platelet cells. SEMA3 signaling results in
modification of the cytokine profile and cellular components of
the immune response. During the acute inflammatory response
SEMA3s can inhibit the recruitment of monocytes and B-cells and
neutralize the functions of platelet cells. Furthermore they may
stimulate DCs and steer them away from the site of injury. On the
other hand at sub-chronic and chronic stages of injury SEMA3s
may restrict an extensive immune response. As mentioned ear-
lier in this review, Sema3A did induce apoptosis of neuropro-
tective M2 macrophages and activated microglia. Furthermore,
Sema3A was able to suppress in vitro the proliferation of recruited
T-lymphocytes and inhibit the synthesis of their cytokines.
Whether these functions occur in vivo as well is yet to be elu-
cidated. In this context, it is plausible that SEMA3s control the
inflammation response both at acute and chronic stages. The
question remains though, whether the immune response is bene-
ficial or detrimental for recovery after traumatic CNS injury.
A possible consequence of SEMA3s expression after CNS
injury is the masking of NRP1 epitopes that could interact
with other ligands like TGF-β. TGF-β can suppress the immune
response at chronic stages by controlling virtually all-immune
cells. From this point of view, SEMA3s may interfere with TGF-
β signaling on the inflammatory cells in scar tissue. Blockage of
class III “immune SEMAs” after CNS injury may therefore result
in unwanted elevated level of the immune response due to the
loss of SEMA3s function. However two potential mechanisms
might counteract these undesired effects: (1) As mentioned ear-
lier in this review blockage of SEMA3s signaling might favor
revascularization and thus the innate ability of the organism for
effective clearance and recycling of the excessive inflammatory
cells through the circulatory pathway; and (2) NRP1 receptors
of inflammatory cells may become available for TGF-β signaling,
which suppress the immune response perhaps more sufficiently
than SEMA3s. Therefore, the role of SEMA3s in modulating
the immune response after traumatic CNS injury needs to be
investigated in more detail.
THE ROLE OF SEMAPHORIN SIGNALING IN RE-MYELINATION
Trauma of the CNS induces mechanical forces that cause loss of
OLs and demyelination of axons at and surrounding the injury
site. The loss of myelin sheaths decreases the conduction velocity
of action potentials and could result in axonal degeneration.
The reestablishment of myelin sheets around demyelinated axons
and around newly sparsely formed regenerating axons, a process
called remyelination, is therefore important to regain neuronal
function after brain and spinal cord injuries (reviewed in Franklin
and Ffrench-Constant, 2008). Traumatic CNS injury leads to
Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 328 | 9
Mecollari et al. Class III semaphorins and nervous system trauma
deposits of myelin debris around the scar and in the denervated
nerve tracts, which leads to additional impairment of functional
recovery. Firstly, myelin-derived axon repulsive molecules such
as Nogo-A, MAG and OMgp, as well as a number of secreted
and membrane bound SEMAs, restrict regrowth of the injured
axons (reviewed in Schwab, 2004; Xie and Zheng, 2008; Lee and
Zheng, 2012). Secondly, myelin debris limits remyelination by
inhibiting the differentiation of oligodendrocyte precursor cells
(OPCs) into new functional OLs (Kotter et al., 2006). Thus,
traumatic CNS injury leads to pathology of the white matter
and restricts regenerative processes such as axon regrowth and
differentiation of OPCs.
Re-myelination does occur in healthy and injury conditions of
the adult CNS. Adult born OLs synthesize new myelin sheaths
but contain shorter and thinner internodes compared to post-
natal born OLs (Hughes et al., 2013; Young et al., 2013). The
typical adult born OL derived myelin sheaths are observed on
demyelinated axons that survive SCI at chronic stages post-injury
(Smith and Jeffery, 2006; Lasiene et al., 2008). After traumatic
CNS injury, two endogenous mechanisms are initiated to remyeli-
nate surviving axons. Firstly, SCI causes proliferation of OPCs
and adult-born OLs initiate remyelination of the naked axons
(McTigue et al., 2001). However, the oligogenesis is limited to the
reactive lesion border after injury (Tripathi and McTigue, 2007).
Secondly, Schwann cells from the peripheral nerves and neuronal
crest precursor cells undergo plasticity changes and migrate to
the spinal cord lesion (Nagoshi et al., 2011). These Schwann
cells provide neurotrophic support and participate in the re-
myelination of surviving axons. Taken together, remyelination
occurs at demyelinated CNS axons that survive traumatic injury,
it is however limited to the peri-lesion neuropil.
Remyelination in the adult CNS requires the activation and
recruitment of OPCs and their differentiation into mature OLs.
Many extrinsic factors, including the immune response, modulate
the function of OPC in the injured CNS. SEMA3s are one of the
molecules known to influence the oligodendrocyte lineage and re-
myelination (reviewed in Kotter et al., 2011). Semaphorins like
SEMA3A and SEMA3F are upregulated in demyelinated lesions
of MS patients and experimental animal models (Williams et al.,
2007). Oligodendrocytes and their precursor cells express NRPs
(NRP1 and NRP2) and a wide range of PLXNs, indicating that
these cell types are sensitive to SEMA3s (Cohen et al., 2003; Okada
et al., 2007; Piaton et al., 2011; Syed et al., 2011; Xiang et al.,
2012; Boyd et al., 2013). Furthermore, demyelination induces
an upregulation of these semaphorin receptors in OPCs in vivo
(Piaton et al., 2011). Therefore it is well documented that the
oligodendrocyte lineage has the ability to respond to injury-
induced SEMA3s in the adult CNS.
One of the potential mechanisms by which SEMA3s act is that
they modulate the guidance of the oligodendrocyte lineage. Stripe
and outgrowth assays have demonstrated that cultured OPCs are
not capable to migrate across high concentrations of Sema3s,
including Sema3A, Sema3B, Sema3C and Sema3F (Cohen et al.,
2003). The same study showed that Sema3B and Sema3C also
repel and collapse processes of cultured OPCs. Another study
demonstrated that Sema3A is repulsive for OPC migration, while
Sema3F enhances the proliferation of embryonic OPCs and has
an attractive effect in vitro (Spassky et al., 2002). The effect of
Sema3A and SEMA3F on OPC migration was confirmed in a
more recent study, in which OPCs were isolated from the adult
brain and spinal cord (Piaton et al., 2011). The migration of
OPCs by Sema3F is mediated by NRP2 and PLXNA3 signaling
in vitro (Xiang et al., 2012). Collectively these data indicate that
most SEMA3s block OPC migration, in contrast to SEMA3F that
accelerates their migration in vitro.
In line with the in vitro studies, the important role of SEMA3s
in OPCs migration was validated in vivo. SEMA3A and SEMA3F
have been increasingly implicated to influence the recruitment of
OPCs and remyelination. In post-mortem tissue, high expression
levels of SEMA3A in MS lesions correlated with low numbers of
OPCs (Boyd et al., 2013). Furthermore, the migration of OPCs
in the CNS has been modified in animal models by changing
the relative expression of Sema3A and Sema3F. More precisely,
viral delivery of Sema3A prior to a demyelination lesion had a
repulsive effect on OPCs, in contrast to Sema3F that attracted
OPCs (Piaton et al., 2011). Similarly, injection of recombinant
Sema3A or Sema3F after induction of a white matter lesion
lead to comparable phenotypes (Boyd et al., 2013). Furthermore,
blockage of Sema3A signaling enhances the recruitment of OPCs,
as validated in two transgenic mice models: (1) NRP1 mutated
in the Sema3 domain (Piaton et al., 2011); and (2) knockdown
of endogenous Sema3A (Boyd et al., 2013). Boyd et al. showed
that reduced expression of Sema3A promoted re-myelination
in vivo. Thus, Sema3A signaling inhibits OPC recruitment in
demyelinated lesions and can impair remyelination. In contrast,
Sema3F mediated OPC recruitment promoted remyelination in
the lesion (Piaton et al., 2011; Boyd et al., 2013). Taken together,
Sema3A is a negative regulator of OPC recruitment while Sema3F
facilitates OPC recruitment in the demyelinated areas in vivo. This
highlights that stimulation of OPC recruitment by manipulating
the expression of these two SEMA3s could promote functional
remyelination.
Another potential mechanism for SEMA3s to block remyeli-
nation is by inhibition of OPC differentiation. Application of
Sema3A to cultured primary OPCs inhibited their differentiation
into OLs. Conveniently, the effects of Sema3A on OPC differ-
entiation were dose-depend and reversible (Syed et al., 2011).
This clearly demonstrates that SEMA3A acts as inhibitor of OPC
differentiation in vitro. SEMA3A could therefore potentially block
differentiation of OPC after demyelination in vivo. Correspond-
ingly, administration of Sema3A ten days after a demyelination
lesion in the adult CNS influenced OPCs and remyelination.
The observations made from Syed et al. indicate that delayed
delivery of Sema3A does not alter the migration but inhibits
OPC differentiation in demyelinated lesions. To add more to this
evidence, a strong impairment of remyelination was observed in
Sema3A infused lesions (Syed et al., 2011). Based on these recent
findings, it is clear that SEMA3A inhibits CNS remyelination and
that one of the mechanisms is the arrest of the differentiation of
OPC at a pre-myelinating state in vivo.
SEMA3A also influences the migration of the alternative type
of myelinating cells in the CNS, the Schwann cells. The study
from Kaneko et al. (2006) documented that Schwann cells are
responsive to SEMA3A by the expression of NRP1, PLXNA1
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and PLXNA4. Furthermore, stripe assays demonstrated that
Sema3A has a repulsive effect on the migration of Schwann cells.
Consistent with the in vitro findings, the in vivo observations
revealed that this repulsive effect of Sema3A on Schwann cells is
suppressed by Xanthofulvin treatment (Kaneko et al., 2006). It is
known that after SCI in adult rat, Schwann cells are capable to
migrate from the periphery to the injury site and start remyelina-
tion (Nagoshi et al., 2011). Xanthofulvin treatment in the injured
spinal cord indeed promoted extensive Schwann cell migration
and remyelination in the lesion site (Kaneko et al., 2006). This
suggests yet another mechanism by which SEMA3A could inhibit
CNS remyelination and that is via inhibition of Schwann cell
migration in vivo.
SEMA3s are not the only ligands of NRPs that have a role
in remyelination. The extracellular domain of NRP1 can form a
receptor complex with EGFRs on the cell surface of tumor cells.
NRP1 regulates clustering of EGFRs and elevates the activity of
their signaling pathway (Rizzolio et al., 2012). It seems plausible
that NRP1 forms complexes with EGFRs at the oligodendrocyte
lineage as well. A study that used a gain and loss of EGFR
function approach showed that EGFR signaling plays a signifi-
cant role in remyelination in adult mice (Aguirre et al., 2007)
by promoting: (1) proliferation of OPCs, (2) migration into
the white matter lesion, (3) adult oligogenesis and importantly
(4) axon remyelination. Appropriately, these pro-remyelination
effects were decreased in transgenic mice with hypoactive EGFR
signaling, as demonstrated in the same study. Hence, enhancing
EGFR signaling could be a strategy to target the regenerative pro-
cesses of remyelination after CNS trauma. As mentioned above,
SEMA3A signaling via NRP1 seems to have opposing effects
on remyelination compared to EGFR. However, it is unknown
whether there is functional competition between both ligands for
NRP1 binding on OLs and if this may influence remyelination.
PDGF is one of the critical growth factors that regulate OPC
proliferation, survival and migration of the OL lineage. PDGF is
therefore suggested to be important for the distribution of OPCs
during development and adulthood (reviewed in Mitew et al.,
2014). PDGF signaling could also have a clinical relevant role since
the PDGF alpha receptors (PDGFαR) are expressed at OPCs in
healthy white matter and active MS lesions of humans (Wilson
et al., 2006). Thus, PDGF signaling on OPCs is associated with
remyelinating areas in the adult CNS of humans. Interestingly
enough, NRP1 has been shown to mediate PDGF signaling in
various cell types including: hepatic satellite cells (Cao et al.,
2010), mesenchymal stem cells (Ball et al., 2010) and vascular
smooth muscle cells (Banerjee et al., 2006; Pellet-Many et al.,
2011). As described earlier, NRPs are expressed in OPCs and
play a significant role in re-myelination. The above studies do
not rule out the possibility that NRP1 may be acting via yet
another non-classical binding partner. Hence, NRP1 dependent
signaling of SEMA3s may additionally counteract PDGF induced
OPC survival, proliferation and migration.
Taken together the above experimental data suggest that
SEMA3s modify the function of the oligodendrocyte lineage.
Multiple SEMA3s inhibit OL migration in vitro. Furthermore,
Sema3A has been shown to inhibit remyelination by blocking the
recruitment of OPCs and their differentiation into myelinating
OLs and could also inhibit the recruitment of Schwann cells. In
contrast to the inhibitory functions of most SEMA3s, SEMA3F
stands out as the only secreted semaphorin that exerts chemo-
attractive properties for OPCs with the potential to promote
remyelination. Future studies should focus on targeting specific
SEMA3s or their receptors as a potential approach to improve
re-myelination. NRP1 could be targeted to enhance remyelina-
tion by inhibiting the function of Sema3A. Blockage of Sema3A
signaling may be beneficial for remyelination by stimulating
OPC recruitment and differentiation at the neural scar. Fur-
thermore, interference with SEMA3A may facilitate EGF and
PDGF signaling via NRP1 and thereby promote remyelination. A
selective inhibitor of SEMA3A-NRP1 signaling would not affect
the pro-myelinating effects of SEMA3F since it signals mainly
via NRP2. Hence, injury-induced SEMA3F may still promote
OPC migration in the lesion site and promote remyelination.
The evidence accumulated from multiple studies in demyeli-
nation lesions, proposes that alternative strategies to promote
remyelination could focus on enhancing SEMA3F mediated
OPC migration, which in combination with boosting EGF and
PDGF signaling might result in sufficient remyelination. Finally,
based on research in the field of MS, it has been suggested
that the acute immune response could promote re-myelination
but this function may be restricted in later stages (reviewed
in Kotter et al., 2011). The high expression of SEMA3s after
2 weeks of traumatic injury correlates strongly with restricted
remyelination.
CONCLUSIONS
This review outlined the functions of SEMA3s and their receptors
in key biological processes that play a prominent role following
traumatic CNS injury, including (1) axonal regeneration; (2) re-
vascularization; (3) immune response; and (4) re-myelination
(Figure 1). SEMA3s and their receptors can affect the aforemen-
tioned processes in both the acute and sub-chronic/chronic stages
of traumatic CNS injury. In the acute phase of CNS injury local
expression of SEMA3s may negatively regulate axonal regenera-
tion by interfering with the neuroprotective functions of VEGFA,
re-vascularization by directly regulating EC adhesion, migration,
proliferation and survival or by suppressing the pro-angiogenesis
effects of VEGFA, immune response by inhibiting the mobil-
ity of monocytes, B-lymphocytes and possibly by silencing the
pro-inflammatory effects of platelet cells, and re-myelination by
arresting close-by OPCs in a premature stage before chronic stages
of injury is initiated.
In the sub-chronic and chronic phase of CNS injury SEMA3s
may inhibit axonal regeneration by inducing apoptosis of neu-
rons and by preventing axons to penetrate scar tissue. They
may also restrict re-vascularization by SEMA3B inhibition of the
recruitment of pericytes that normally stabilize new blood vessels
and by SEMA3A mediated elevation of the vascular permeability
of blood vessels even when the expression of VEGFA declines.
This increased vascular permeability may have a direct impact
on the chronic immune response where SEMA3s are shown to
inhibit the proliferation of recruited T-lymphocytes and antago-
nize the synthesis of cytokines such as IL-2, IL-4, IL-10 and IFNγ.
Furthermore SEMA3A induces apoptosis of microglia that
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FIGURE 1 | Class III semaphorins exert regulatory functions in multiple
processes after CNS trauma by modulating various neuronal and
non-neuronal cell types. Deposition of SEMA3s (black arrows) by invading
fibroblasts from the ruptured meningeal layer and axotomized neurons has a
large consequence for cellular remodeling and wound healing. The secreted
SEMA3s have a wide range of biological effects on the resident glial cells and
neurons, and additionally affect the blood derived cells that infiltrate the lesion
core as a result of blood vessel rupture. As discussed in this review, the role
of SEMA3s goes beyond inhibiting axonal regeneration and could be a
significant target for future studies to stimulate repair following CNS trauma.
Abbreviations: B-cell, B-lymphocyte; EC, endothelial cell; EGF, epidermal
growth factor; OL, Oligodendrocytes; OPC, oligodendrocyte precursor cells;
PDGF, platelet-derived growth factor; SC, Schwann cells; T-cell, T-lymphocyte;
TGF-β, transforming growth factor—beta.
express NRP1 and thereby influence the survival and axonal
regeneration capacity of injured CNS neurons. Additionally
SEMA3A induces cell death of M2 macrophages and could
thereby induce a “pro-inflammatory” M1 macrophage environ-
ment in the scar. An intriguing but yet not fully established
hypothesis is that SEMA3s might modulate TGF-β non-canonical
signaling via NRPs at inflammatory cells near the scar tis-
sue. Finally, re-myelination is also affected by SEMA3s at the
chronic stages of injury. In particular SEMA3A inhibits the
recruitment and differentiation of OPCs and inhibits the mobil-
ity of migrating Schwann cells. In contrast, SEMA3F promotes
OPC migration and remyelination. Lastly, SEMA3A signaling
via NRP1 might antagonize furin-processed SEMA3F, EGF and
PDGF signaling pathways that all posses the ability to stimulate
remyelination.
PERSPECTIVES
Since the discovery of Sema3A in 1993, SEMA3s signaling and
their receptors were increasingly recognized to be involved in key
processes influencing axonal outgrowth and guidance. However,
substantial evidence indicates that SEMA3s also participate in
cell-to-cell communication systems that underlie angiogenesis,
inflammation and re-myelination. It will be necessary to combine
the knowledge obtained from the research fields of vascular
biology, cancer biology, immunology and glial biology in order to
better understand the role of SEMA3s signaling in CNS trauma. A
combinatorial approach involving these fields of research may be
necessary in order to move closer towards a therapy for traumatic
CNS injury. SEMA3s are an important target in strategies that aim
to repair traumatic spinal cord and brain injuries, however the
sometimes overlooked pleiotropic nature of their NRP receptors
needs to be addressed/understood in a more thorough fashion in
future studies.
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